Best in Class Case Study- Big Data & Cancer Research

Tags: Cancer research UK Cancer Treatment discovery Allan Jordan Cancer Research Manchester Institute Drug Discovery genome sequencing Big Data big data in pharma Chemotherapy research chemotherapy genomic data

Pharmaceuticals & Biotechnology Editor
06/25/2015

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

As of now, big data is not utilised as often and as well as it could be in the Pharmaceutical Industry.Data usage could lead to accelerated drug discovery and better help patients, enabling companies to streamline, become more productive, more efficient, and reduce costs. Allan Jordan strongly believes that while big data is important and can change Pharma, it should not just be gathered without reason. There needs to be a purpose, and purpose is the main thing driving his latest project.

The project in question is focused on exploiting genome sequencing efforts to discover new targets for cancer treatment. Allan and his team are working to combine unexploited genomic data with a new concept called collateral vulnerability to try and find weaknesses within tumour cells. This is a huge opportunity for positive change. The goal is finding treatments for cancer patients who haven’t had ideal responses to chemotherapy